Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression.

ABSTRACT:

Background

Multiple myeloma (MM), like other cancers, is caused by the accumulation of genetic abnormalities. Heterogeneity exists in the patients' response to treatments, for example, bortezomib. This urges efforts to identify biomarkers from numerous molecular features and build predictive models for identifying patients that can benefit from a certain treatment scheme. However, previous studies treated the multi-level ordinal drug response as a binary response where only responsive and non-responsive groups are considered.

Methods

It is desirable to directly analyze the multi-level drug response, rather than combining the response to two groups. In this study, we present a novel method to identify significantly associated biomarkers and then develop ordinal genomic classi

SUBMITTER: Zhang X 

PROVIDER: S-EPMC5946496 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature